A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia

A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia

Abstract RAD51 recombinase activity plays a critical role for cancer cell proliferation and survival, and often contributes to drug‐resistance. Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel of cancers, including breast cancer and ch...

Full description

Bibliographic Details
Main Authors: Jiewen Zhu, Longen Zhou, Guikai Wu, Heiko Konig, Xiaoqin Lin, Guideng Li, Xiao‐Long Qiu, Chi‐Fen Chen, Chun‐Mei Hu, Erin Goldblatt, Ravi Bhatia, A. Richard Chamberlin, Phang‐Lang Chen, Wen‐Hwa Lee
Format: Article
Language:English
Published: Springer Nature 2013-01-01
Series:EMBO Molecular Medicine
Subjects:
cancer
CML
inhibitor
RAD51
small molecule
Online Access:https://doi.org/10.1002/emmm.201201760

Internet

https://doi.org/10.1002/emmm.201201760

Similar Items